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The concept of Cancer of Unknown Primary (CUP) has evolved with the advent of medical oncology. CUP can be
difficult to diagnose and represents 2 to 5% of new cancers, therefore not exceptionally rare. Within CUPs can be
identified a subset of favourable prognosis tumours, however the vast majority of CUP patients belongs to a poor
prognosis group.
CUP features significant oncological challenges, such as unravelling biological and transversal issues, and most
importantly, improving patient’s outcomes. In that regard, CUP patients’ outcomes regrettably showed minimal
improvement for decades and CUP remains a cancer group of very poor prognosis.
The biology of CUP has two main hypotheses. One is that CUP is a subgroup of a given primary cancer, where
the primary is present but cannot be seen due to its small size. The other, the “true” CUP hypothesis, states that
CUP share features that make them a specific entity, whatever their tissue of origin. A true biological signature
has not yet been described, but chromosomal instability is a hallmark of poor prognosis CUP group.
Precision oncology, despite achieving identifying the putative origin of the CUP, so far failed to globally
improve outcomes of patients. Targeting molecular pathways based on molecular analysis in CUP management is
under investigation. Immunotherapy has not shown ground-breaking results, to date. Accrual is also a crucial
issue in CUP trials.
Herein we review CUP history, biological features and remaining questions in CUP biology, the two main
approaches of molecular oncology in CUP management, in order to draw perspectives in the enormous challenge
of improving CUP patient outcomes.

Introduction

dormant or regressed, primary [2].

An enigmatic entity, cancer of unknown primary (CUP), has evolved
alongside the development of modern oncology. The first mention of
cancer with “unknown primary” dates back to 1946 [1]. Since that time,
a shift in the definition and diagnosis occurred, associated with the
emergence of ever more sophisticated diagnostic tools which aim to
trace biological and molecular similarities to the elusive, possibly

Epidemiology - prognosis
Epidemiology
CUP is defined by the absence of a clinically identified primary lesion
(the primary is not “seen”) at the time of diagnosis despite standardised

* Corresponding author.
E-mail address: timothee.olivier@hcuge.ch (T. Olivier).
1
Senior authors of equal contribution.
https://doi.org/10.1016/j.ctrv.2021.102204
Received 12 January 2021; Received in revised form 27 March 2021; Accepted 30 March 2021
Available online 5 April 2021
0305-7372/© 2021 The Author(s).
Published by Elsevier Ltd.
This is an
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

open

access

article

under

the

CC

BY-NC-ND

license

T. Olivier et al.

Cancer Treatment Reviews 97 (2021) 102204

diagnostic work-up [3–5].
Confirmed CUPs represent 2 to 5% of all cancers [5] and 15% of all
new cancers are presenting as malignancy of unknown origin (MUO)
[4].
CUPs incidence is varying across countries [5]. Differences may be
explained by coding rules and methodology in cancer registries [6]. Cost
issues can explain underreporting of CUP: in the US, costs are better
covered for specific cancers in comparison with CUPs [7]. In contrast,
CUP incidence has been related to be higher in patient with lower in
come, possibly due to insufficient diagnostic inquiry [7,8].
Incidence has increased since CUP concept was introduced, to reach
a peak at the end of 1990′ s in most countries [5]. After the tipping point,
the decreasing number of diagnosed CUPs is mainly explained by better
identification of small primary lesion. Decreased incidence of some
primary cancers (lung) could also account in the decrease in CUPs
incidence.

- well-differentiated neuroendocrine tumour of unknown primary
- peritoneal adenocarcinomatosis of a serous papillary in females
- isolated axillary nodal metastases in females
- squamous cell carcinoma (SCC) involving non-supraclavicular
cervical lymph nodes (head-and-neck)
- CUP with a colorectal profile (immunohistochemistry (IHC) or
molecular)
- single metastatic deposit from unknown primary
- men with blastic bone metastases or IHC/serum PSA expression,
- isolated inguinal adenopathy (SCC)
Prognosis is better in these entities, with curative intent in some of
them. As an example, the isolated axillary nodal metastases will be
treated like a primary breast cancer with 3-year survival rate up to 97%,
and women with peritoneal carcinomatosis of a serous papillary
adenocarcinoma will have outcomes in the range of stage III and IV
ovarian cancer patients [10].

Favourable And Unfavourable Subgroups Of CUPs

Prognosis in the unfavourable subgroup of CUPs

CUP can be divided in two subgroups with very different prognosis,
treatment, and expected outcomes: the favourable (15–20%) and the
unfavourable (80 – 85%) subgroups [3,9].
For patients presenting with CUPs belonging to the favourable sub
group, principles of treatment are mostly derived from the treatment of
their corresponding known primaries. Nine specific situations are
identified to belong to the favourable subgroups, with a corresponding
tailored treatment recommendation based on the equivalent known
primary tumour. This is well described in international guidelines
[3,9,10], this situations are:
- poorly differentiated neuroendocrine carcinomas of unknown
primary

Table 1 describes outcomes from randomized trials in CUPs. Early
trials reported dramatically short median survival (few weeks). In more
recent trials within the unfavourable subgroup, median overall survival
is around 1 year, up to 13.6 months [11]. Such discrepancy may reflect
changes in inclusion criteria, and a strong selection bias favouring
enrolment of patients with better prognosis in recent trials.
Prognosis of CUP patients is generally worse than those with known
primary cancers [12]. Among the unfavourable subgroup of newly
diagnosed CUP patients, the most widely used prognostic model is based
on the LDH level and the performance status (PS), separating a good
prognosis group (PS = 0–1, normal LDH or absence of liver metastasis if
LDH unknown) with a predicted 11.7 months median survival, and a

Table 1
Randomized clinical trials studying specifically CUP.
Author (year) (number of
patients)

Histology

Regimens

Median overall survival
(months)

Response
rate

p

Woods et al. (1980) 75
(n = 47)

Adenocarcinoma,
undifferentiated

1.6

4.5%

NS

Shildt et al. (1983) 76
(n = 36)

Adenocarcinoma

4.1
3.4
3.1

36%
0%
0%

NS

Milliken et al. (1987) 78
(n = 101)
Eagan et al. (1987) 77
(n = 55)
Falkson et al. (1998) 79
(n = 84)
Dowell et al. (2001) 80
(n = 34)
Assersohn et al. (2003) 81
(n = 88)
Culine et al. (2003) 83
(n = 80)
Palmeri et al. (2006) 11
(n = 66)
Huebner et al. (2009) 84
(n = 92)
Hainsworth et al. (2010) 85
(n = 198)

Adenocarcinoma,
undifferentiated
Carcinoma (50/55
adenocarcinomas)
Adenocarcinoma,
undifferentiated
Adenocarcinoma,
undifferentiated
Carcinoma

4.1
5.7
5.5
4.6
9.4
5.4
8.2
6.4
6.6
4.7
8
6
13.6
9.6
11
6.9
7.4

42%
32%
14%
27%
50%
17%
19%
19%
11.6%
20%
55%
38%
48.5%
42.3%
23.8%
20%
18%

Gross-Goupil et al. (2012) 86
(n = 52)
Hainsworth et al. (2015) 74
(n = 89)

Carcinoma

5-Fluorouracil, cyclophosphamide,
methotrexate
Doxorubicin, mitomycin-C
5-Fluorouracil
Doxorubicin, 5-fluorouracil,
cyclophosphamide
Doxorubicin, mitomycin-C
Cisplatin, bleomycin, vinblastin
Doxorubicin, mitomycin-C
Cisplatin, doxorubicin, mitomycin-C
Cisplatin, epirubicin, mitomycin-C
Mitomycin-C
Paclitaxel, 5-fluorouracil, leucovorin
Carboplatin, etoposide
5-Fluorouracil
5-Fluorouracil, mitomycin-C
Cisplatin, gemcitabine
Cisplatin, irinotecan
Cisplatin, gemcitabine, vinorelbine
Cisplatin, paclitaxel, gemcitabine
Carboplatin, paclitaxel
Gemcitabine, vinorelbine
Paclitaxel, carboplatin, etoposide then
gefitinib
Gemcitabine, irinotecan then gefitinib
Cisplatin
Cisplatin, gemcitabine
Carboplatin, paclitaxel, belinostat
Carboplatin, paclitaxel

8.5
8
11
12.4
9.1

18%
16%
19%
45%
21%

Hayashi et al. (2019) 88
(n = 130)
Fizazi et al. (2019) 89
(n = 243)

Carcinoma

Carboplatin, paclitaxel
Site-specific therapy
Cisplatin, gemcitabine
Site-specific therapy

12.5
9.8
10
10.7

41.2%
34.7%
NA

Carcinoma
Carcinoma
Adenocarcinoma,
undifferentiated
Carcinoma

Carcinoma

Carcinoma

NS
NS
0.05
NS
NS
NS
NS
NS
NS
NS
NS OS
P less than 0.02
ORR
NS
NS

p = p-value for statistical significance for overall survival; NS = not statistically significant, OS = overall survival, ORR = overall response rate, NA = not available
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poor prognosis group (PS > 1 or elevated LDH) with 3.9 months median
survival [13]. This model was based on retrospective data, with a third
of patients included being part of prospective trials, with probably
overestimation of survival in comparison with real world outcomes.
Indeed, data from the Surveillance, Epidemiology, and End Results
(SEER) registry analysis up to 2008 shows dismal survival after CUP
diagnosis with a median survival of 3 months, making CUP the fourth
more lethal cancer in the world [8].
Over time, there were almost no improvement in prognosis [14],
with survival improving only in the subset of patients with squamous
cell carcinoma [8]. Within this study, there is no distinction between the
favourable and unfavourable subgroup of CUPs: it is likely that most of
the patients were belonging to the unfavourable subgroup of CUPs. The
longitudinal analysis of the SEER registry (1973 to 2008) showed a
better survival (after multivariate analysis) for white race, female, age
under 65, married people, squamous histology, diagnosis done in the
most recent decade, and treatment with radiotherapy [8].

generation sequencing), a putative tissue of origin can be identified in
approximately 80%-85% of cases [15,16].
An integrative illustration of these definitions and of the way the
diagnostic work-up of CUP is currently shaped is presented in Fig. 1.
Tissue Of Origin Classifier Assays
Driven by the hypothesis that the identification of a primary tumour
could lead to more specific treatment and therefore would improve
patient’s outcomes, several molecular assays were developed in order to
identify the tissue of origin in CUPs with more accuracy.
Based on gene expression profiling, miRNA expression or DNA
methylation analysis, these tests compare the molecular features of the
CUP to the molecular profile of tumours of known origin, therefore
inferring a putative tissue of origin. Because no gold standard test
defining the tissue of origin exists in CUP, the assessment and validation
of the performance of these classifiers are challenging [2,20].
Several retrospective studies have attempted to assess the prediction
accuracy of these tests performed on biopsy specimens from patients
with CUP. Using correlation with clinicopathological features, the IHC
profile or the identification of a latent primary as prediction comparator,
these molecular based tissue of origin classifiers yield prediction accu
racy from 60% to 92% [15,21–30]. This is corroborated by a prospective
study demonstrating an 84% agreement of molecular profile with clin
icopathological diagnosis [31].
One approach, illustrated by the work of Moran et al., is based on the
epigenetic profiling via analysis of DNA methylation, developing an
assay called EPICUP® DNA methylation profiling. This was developed
from the analysis of 2790 tumour samples and validated in 7691 known
tumour samples, with 87% prediction of a primary [27].
MicroRNA profiling is another technique, that has been studied in a
prospective study [31]. The analysis of formalin-fixed paraffinembedded (FFPE) metastatic tissues from 104 patients using a subset of
48 microRNAs led to a 71% accuracy in predicting the tissue of origin.
Ferracin et al. used a similar approach with a 47-miRNA signature,
reaching a 100% accuracy for primary tumours and 78% for metastasis
from known primary tumours, with an accuracy for CUP tested in only
16 patients [24].
Another approach is based on the analysis of gene expression
profiling. Horlings et al. obtain whole gene expression data using
microarray technology from FFPE classifying correctly 81% of metas
tasis to their known primaries. A primary origin was assigned in almost
94% of ACUP (adenocarcinoma of unknown primary origin) [22]. Even
if the microarray technology is not the most used today, this study

Diagnosis And The Tissue Of Origin Concept
Diagnosis is established after pathological examination of a good
quality tissue sample (biopsy or, more rarely, cytology). Diagnostic
workup aims to exclude non-carcinomatous tumours (lymphomas,
melanomas, germ cell tumours, sarcomas), which account for less than
5% of findings, but point towards the elusive primary and require very
specific treatments. Consequently, CUPs are almost exclusively carci
nomas, explaining why the term CUP is also used for “carcinoma” of
unknown primary origin.
The availability of advanced imaging and endoscopy technologies,
serum marker testing, the development of immunohistochemical panel
testing and the increasing access to gene profiling and other molecular
analyses, including epigenetics [15,16] allow suspecting a tissue of
origin in a growing subset of CUPs, even in the absence of anatomically
identified primary [17,18]. The European Society of Medical Oncology
(ESMO) guidelines suggest a basic immunohistochemical (IHC) work-up
for CUPs, divided in a minimum set of primary markers, to initially
direct towards subsets of potential primaries, followed by a set of
additional markers towards the final identification of the putative pri
mary tumour, endorsing a previously described two-step procedure
[3,19]. Two CUP groups can be distinguished: tissue of origin-defined
CUP and unclassifiable CUP [17], the latter corresponding to the
confirmed CUP for which neither an identifiable primary site nor a
suggested tissue of origin exists.
With the use of more advanced assays (such as microarrays and next

Fig. 1.
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confirmed that gene expression analysis can yield high predictive ac
curacy in determining tissue of origin in CUPs.
Some limitations in the analysis of gene expression in CUP could be
overcome by performing more sophisticated analysis, allowing more
comparison with available datasets for all tumour cases. These types of
approaches were implemented in a recent study, with machine learning
analysing 77,044 DNA sequencing and whole transcriptome data. Even
with such sophisticated tools, this yields in 71.7% of prediction in CUPs.
This approach also have the originality to provide, at the same time,
results about potential targetable genomic alteration [30].

primary tumour [33,39]. Many of these genome aberrations originate
from a persistent rate of chromosome missegregation during cell divi
sion, a phenomenon known as Chromosomal Instability (CIN) [40,41],
which in turn can lead to whole chromosome losses and gains (aneu
ploidy) [42] or to other dramatic genome aberrations. It is recognised
that CIN drives cancer aggressiveness by increasing tumour heteroge
neity and genetic diversity within the tumour cell population, which
allows adaptation to unfavourable conditions and therapy resistance
[43] not only to conventional chemotherapy, but to immunotherapy as
well [44]. Furthermore, CIN has been suggested to directly drive the
metastatic process itself [45], and is associated with poor clinical out
comes [39,46,47].
Tumour metastasis is a clonal process driven by CIN, through which
metastatic cancer cells acquire chromosome segments that encode genes
endering survival benefit and metastasising potential [45,48]. A work
conducted by Vikesa and colleagues showed that CUPs, in comparison
with metastases of known origin, presented microRNA signatures of CIN
[49]. While reviewing details from the 57 cases that are described, we
estimate that only 4 of them could have belong to the favourable sub
group of CUP (3 colon cancer and 1 cervical cancer presenting with
inguinal lymph node), suggesting that CIN is exclusive to the poor
prognosis subgroup of CUP but this should be confirm in other studies. It
can therefore be postulated that CIN facilitates independent progression
of metastatic sites in CUP following early dissemination and primary
tumour regression/dormancy (possibly as the latter are less chromoso
mally instable). One could hypothesise that this could be a consequence
of early CIN increase accumulating already in locally advanced primary
tumours, which then could either grow enough in size to be detectable or
stay genomically unstable but small in size, challenging identification,
or even experience regression while some cells have been able to
disseminate to distant organs. This scenario would fit well with the most
predominantly mutated gene found in CUPs, the TP53 gene. Such mu
tations, if acquired early during tumorigenesis could allow permissive
conditions for accumulation of CIN and derived alterations, allowing
cancer cells to continue diving and propagating instead of being elimi
nated [50,51]. The prevalence of TP53 mutations in CUPs is found to be
in the same range as the average TP53 mutation rate across all tumour
types (TP53 is mutated in approximately 50% of all human cancers [52].
In favour of fast genetic evolution increasing aggressiveness in CUPs,
the role of other CIN-related events such as chromothripsis could be
considered. It has been recently postulated that even one single wrong
chromosomal segregation in one cell division can lead to a mutational
cascade fuelling evolution and subclonal heterogeneity in cancers [53],
suggesting that clonal evolution of tumours could in fact start very early.
Although CIN accelerates phenotypic adaptation under selective
pressures, very high CIN levels are counter-productive for tumour sur
vival owing to frequent generation of unviable phenotypes. In this
context, it is CIN tolerance and attenuation mechanisms that allow an
optimal equilibrium and sustainable CIN propagation[43].
It would, therefore, be of interest to investigate CIN levels in CUPs as
a potential explanation for their specific nature and behaviour.
Some studies indicate that cytotoxic therapies induce CIN, and
combination therapy with taxanes may synergize together [54,55].
In our view, early dissemination in the parallel progression, along
with early chromosomal instability in metastatic clones or at the level of
locally advanced disease, has biological robustness and could be hall
marks of CUP tumorigenesis. We provide an illustration of this notion in
Fig. 2. The existence of other pro-metastatic hallmarks/signatures that
could transcend tissue of origin signature in CUPs is not excluded and
could lie in other “-omics” levels (DNA methylation, histone acetylation,
proteomics, non-coding regions) [38,56]. Even in the absence of final
answers on the biology of CUP, recognising the possibility of the “true
CUP hypothesis” could be important for clinicians in the direction of
avoiding endless diagnostic work-up (in order to find the primary) in
patients requiring rapid treatment initiation. Furthermore, considering
the relevant role of CIN in the aggressiveness of CUPs, it could serve in

Biological landscape
Biological hypothesis
Tumorigenesis of CUPs, and how to explain the absence of a
detectable primary, remain matters of debate, with two main hypotheses
[32,33]. The first hypothesis considers each CUP as a subtype of its
corresponding known primary cancer with a primary lesion too small or
too difficult to detect. This disease would, therefore, share clinical fea
tures with the corresponding primary and could benefit from the same
treatment. An example is high-grade serous peritoneal carcinoma that
could arise from early lesions in the Fallopian tube. These early lesions
are undetectable if extensive sampling of the Fallopian tubes is not
undertaken.
The second hypothesis suggests that the absence of the primary
lesion is real, and will persist during the course of the disease, most
probably due to its early and maintained regression or dormancy. CUPs,
in relation to these early biological events, would be a specific entity,
and share similarities whatever their tissue of origin, making them a
complete distinct entity from known primary tumours: this is the “true”
or “genuine” CUP hypothesis [32,33]. The parallel progression model of
tumorigenesis could support this hypothesis, as independent clonal
evolution under differential selection pressure could explain the
regression of a primary lesion (that could be immune-mediated [34])
along with growing metastatic lesions [35,36].
Favouring the first hypothesis, a number of CUP patients (ranging
from 4% to 25% in the reported literature) will subsequently, during the
course of the disease, present a primary lesion [2]. Furthermore, autopsy
studies led to identification of a primary lesion in 73% of CUPs cases,
with variation across studies [20]. Nevertheless, a substantial group of
CUP patients remains without an identified primary lesion.
The ability of molecular classifiers to infer a tissue of origin in the
vast majority of cases argues in favour of biological proximity between
CUPs and known primary cancers [37]. Moreover, a study that
compared microRNA profiles of CUPs metastases with those from pri
mary tissue-matched metastases of known primaries did not detect
substantial differences. An important limitation of this work was that all
CUPs cases were belonging to the favourable subgroups of CUPs [38].
Nevertheless, discrepancies between putative primary lesions found
in autopsy studies and through molecular analyses cast doubt on their
perfect reliability, even though those studies were not conducted at the
same periods of time [33]. Several works failed to identify a unique
“molecular CUP signature” [2,32], consequently weakening the “true”
CUP hypothesis.
Chromosomal instability as a hallmark of CUPs?
The “true” CUP hypothesis states that CUPs, whatever their cell-oforigin, share similarities and could be addressed as a specific entity.
Unfavourable CUPs are definitively sharing clinical characteristics that
distinguish them from other cancers: aggressive phenotype with rapid
growing metastases, unpredictable metastatic pattern, poor response to
chemotherapy and poor clinical outcomes [20]. CUP metastases occur
early and subsequently undergo genetic evolution toward a highly
complex and unbalanced cytogenetic aberrations independent from the
4
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Fig. 2.

the future as an important diagnostic marker as well as a targetable axis
in these types of tumours.

targetable shows wide discrepancy according to studies, varying from
15% to 85% [57,60,63–69]. Such analyses highlight the need to keep a
high level of stringency in defining a “clinically relevant” alteration,
which should go beyond bio-plausibility, and ideally rely on improved
clinical outcomes associated with targeting such alterations, but also
access to relevant approved targeted agents in diverse healthcare
settings.
The NOMINATOR study assessed the feasibility of genomic testing in
rare cancers [70], also assessing actionability as per the OncoKB anno
tation [62]. This work optimistically reports 56% of rare tumours with at
least one actionable finding. The most commonly found aberrant genes
included TP53 (44%), CDKN2A/B (14%), RB1 (14%), PTEN (13%) and
NF1 (12%). However, in order to obtain this high percentage of
actionable findings, the authors included OncoKB level 1 to 4; if the
analysis was to be restricted to biomarkers with at least compelling
clinical evidence of utility (rather than including Level 4 alterations for
which only compelling biological evidence exists), the respective per
centage would be 27%. The authors also exclude from their analysis the
patients in whom the analysis could not be done (initial attrition rate of
18%), introducing therefore an overestimation in the estimation of
percentage of “clinically relevant” alterations. Furthermore, only 13 out
of 121 (11%) patients ultimately had access to a matched drug, and
outcomes are not reported, hence the real impact strength was not
accurately assessed.
Results are awaited for the RP-1843 Arcagen collaborative project of
the EORTC-SPECTA cohorts [71], aiming to perform comprehensive
molecular analysis in a 2100-strong cohort of rare cancer patients. An
initial report of 87 patients with sarcoma, thymic cancer, rare ovarian
and head or neck cancers reported a 47% incidence of clinically relevant
genomic alteration, with a 14% analysis failure rate [72].

Genomic alteration in CUPs
Several studies retrospectively examined the genomic landscape of
CUPs through DNA profiling (Table 2).
In a large retrospective cohort (1806 patients), Gatalica and col
leagues found EGFR and ERBB2 amplification as the most common
amplifications. TP53 (38%) and KRAS (18%) were the most common
mutated genes [57]. A retrospective analysis of 303 CUP patients whose
archival tumour specimens underwent next-generation sequencing
revealed that 32% would have been potentially eligible for the available
molecularly guided targeted or immunotherapy treatment options [58].
This technology is the basis for target identification and management
strategy in the ongoing CUPISCO trial (NCT03498521, see below).
Among 333 patients with CUPs evaluated in Memorial Sloan Kettering
Cancer Center (MSKCC), 150 of them had a genomic analysis through
the inclusion in MSK-IMPACT [59]. The most commonly mutated genes
were TP53, KRAS, CDKN2A, KEAP1, and SMARCA4. Authors identified
45 (30%) patients with potentially targetable alterations and 15 (10%)
actually received targeted therapies. Among the latter, time to treatment
failure ranged from less than 1 month to 14 months [60].
The means through which these alterations could be detected is a
major subject of research. Liquid biopsy techniques offer many advan
tages, notably in cases of no or minimal archival tissue availability [2].
At the 2020 annual meeting of the American Society of Clinical
Oncology (ASCO) the results of cell-free DNA analysis from the largest
cohort to date of in CUP patients were presented [61]. In their work,
90% of patients had at least one cell-free DNA (cfDNA) alteration. When
classifying alterations according to the OncoKB annotation [62], the
authors found that 46% of patients with at least one alteration were
presenting with level 1, level 2B or resistance alteration (level R1).
Importantly, 22% of the patients with at least 1 cfDNA alteration pre
sented at least one Level 1 alteration (FDA-recognised biomarker pre
dictive of response to FDA-approved drug in this indication), such as
PIK3CA oncogenic mutations (22%), ERBB2 amplification (13%),
BRCA1 (7%) and BRCA2 (9%) oncogenic mutations, BRAF V600E mu
tation (8%) and ALK fusion (2%), amongst others [61].
Interpretation regarding whether these mutations could be

Immune microenvironment and immune biomarkers in CUPs
Few data are available on tumour immune microenvironment in
CUPs. One study reported no prognostic value of the presence of CD8
positive tumour–infiltrating lymphocytes (TILs) by IHC on a cohort of 92
CUPs. Transcriptional analysis on 71 cases revealed two sub-groups:
inflamed and non-inflamed. Interestingly, there was inverse associa
tion between levels of VEGF-A gene and inflamed phenotype, suggesting
that VEGF blockade may enhance anti-PD1/PD-L1 in CUPs [73].
5
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Table 2
Genomic alterations identified within CUP tissue analysis.
Author (year)
(number of
patients)

Gene mutations

Ross et al. (2020)
58

(n = 303)

Galatica et al.
(2018) 66
(n = 389)
Clynick et al.
(2018) 68
(n = 21)
Varghese et al.
(2017) 60
(n = 150)
Subbiah et al.
(2017) 69
(n = 17)
Löffler et al.
(2016) 67
(n = 128)
Ross et al. (2015)
63

(n = 200)
Pentheroudakis
et al. (2014) * 65
(n = 87)
Galatica et al.
(2014) 57
(n = 1806)

Tothill et al.
(2013) 64
(n = 16)

Table 3
Investigational predictive biomarkers of response to immune checkpoint in
hibitors in CUP.

Chromosomal abnormalities
Amplifications

Deletions

TP53 (55%); KRAS
(27%); MYC
(23%); CDKN2A
(19%); ARID1A
(11%); MCL1
(10%); PTEN (7%);
PIK3CA (9%);
ERBB2 (8%); BRAF
(6%); NF1 (4%)
TP53 (54%); KRAS
(22%); ARID1A
(13%); PIK3CA
(9%); CDKN2A
(8%)
TP53 (47%); KRAS
(12%); MET (12%)

CDKN2A; CDKN2B;
MTAB; MYC; RAD21;
ERBB2

FGFR2;
CDKN2A;
STK11;
SMARCA4

TP53 (~50%);
KRAS (~25%);
KEAP1 (15%)
TP53 (29%);
ARID1A (18%);
PIK3CA (18%)
TP53 (55%);
CDKN2A (9%);
KRAS (16%); BRAF
(5%); EGFR (4%)
TP53 (55%); KRAS
(19%); ARID1A
(11%); PIK3CA
(7%); BRAF (6%);
ERBB2 (4%)
CTNNB1 (20%);
KRAS (12%);
PIK3CA (9%); MET
(7%); BRAF (6%)
TP53 (38%); KRAS
(18%); BRCA2
(~11%); PIK3CA
(~9%); STK11
(~6%); cKIT (1%);
EGFR (less
than1%)
TP53 (62%); GNAS
(25%); NOTCH1
(18%); PIK3CA
(18%); CDKN2A
(12%); KRAS
(12%);

CCND1 (5%); FGF
(3%); ERBB2 (3%);
MYC (3%)

ND

MYC (12%); CCND1
(6%); FGFR1 (6%)

ND

KRAS (2%); TERT
(2%)

CDKN2A/B
(12%)

SOX2 (18%); CCND1
(12%)

CDKN2A/B
(17%)

FGFR3 (5%); NRAS
(5%); ERBB2 (4%);
MET (4%); EGFR
(2%); KRAS (2%)
MYC (12%); MCL1
(11%); ERBB2 (4%)

CDKN2A
(15%); RB1
(7%)

ND

ND

EGFR (17%); PIK3CA
(14%); ERBB2 (5%);
cMET (1%)

ND

JAK2 (6%); CCDN1
(6%); VHL (6%)

CDKN2A
(6%); BRCA1
(6%); STK11
(6%)

Ross et al. (2021) 58
(n = 303)
Galatica et al. (2018)
(n = 389)

66

PD-L1 expression ≥ 50%: 14%
TMB high: 11.6%
MSI-high: 1%
TMB High : 11.8%
MSI-H : 1.8%
PD-L1 expression ≥ 5%: 22.5%

TMB high: Tumor mutational burden ≥ 16 mutations/megabase.
MSI-H : microsatellite instability high

doublet chemotherapies with new compounds, are accepted standard
“empiric” chemotherapy regimens in international guidelines [3]. They
should be selected according to local expertise and facilities and
considering toxicity profiles and patient comorbidities.
Table 1 presents all existing randomized trials specifically studying
CUP patients, with the regimens and their respective median overall
survival and response rates when available [11,74–89]. As described,
the prognostic classification (based on performance status and LDH
levels) separates a favourable prognosis subgroup (median survival of
12 months) from a poor prognosis subgroup (median survival of 4
months); for the latter, best supportive care should also be considered
upfront in the management algorithm [3,13].
A systematic review of randomised trials, excluding data from the
specific favourable subsets of CUPs, showed no significant benefit for
any treatment group over others (including platinum compounds, tax
anes, gemcitabine, vinca-alkaloid and irinotecan). Hazard ratios for
death of combination treatments containing taxanes, platinum or both
showed a favourable trend over monotherapy with agent other than
platinum or taxanes [90]. Another meta-analysis based on 32 studies
showed a trend toward better survival outcome with platinum or taxane
treatment. After adjustment for prognostic factors this trend was no
longer significant for platinum vs non-platinum based regimen, while
taxane-based regimens remained significant [91].
A phase III trial in 198 patients compared a triplet combination
(paclitaxel/carboplatin/etoposide) with a gemcitabine/irinotecan
combination: the triplet regimen was not superior and more toxic [85].
Doublet chemotherapy seems better than monotherapy regarding
objective response rate (ORR) and is the first choice when feasible [92].
However, this has not been prospectively proved to be significant [86].
In further lines, chemotherapy is for a very selected population, with
no trials featuring best supportive care as a comparative arm. Response
rates are usually around 10% with median OS ranging from 3 to 9.7
months [92].

CKN2A/B
(11%)

ND, not documented, *CTNNB1, MET, PIK3CA; KRAS, BRAF targeted
sequencing

Tissue of origin-based chemotherapy
If CUPs share a “biological signature”, they would behave similarly
whatever their tissue of origin. On the contrary, if CUPs are rather a
subgroup of their corresponding primary, patients would benefit more
from a tissue of origin-tailored treatment. In favour of the last hypothesis
is the subgroup of specific subset of favourable CUPs, mainly composed
of subtypes of entities that are closed to their known primary.
A substantial proportion of CUPs present with relatively chemoresistant tissue of origin tumours (pancreas, biliary tract) [20]. Other
CUPs, presenting with chemosensitive tumours (ovarian, breast), will be
likely to respond to “empiric” chemotherapy whatever their tissue of
origin. Treatment strategies for certain primaries have considerably
changed during the last decades, as for lung cancer, with checkpoint
inhibitors (CPI) and tyrosine kinase Inhibitors (TKI) being incorporated
into standard-of-care. Hence, a randomised trial comparing the efficacy
of “empiric” chemotherapy to a “classifier-directed treatment” was
required.
A large prospective non-randomized phase II trial studied outcomes
of 194 patients CUP patients receiving assay-directed site-specific

Another study analysed 592 genes of 389 CUPs cases, showing that 28%
of them had at least one potential predictive biomarker to CPI response,
such as PD-L1 overexpression, MSI-H profile, or high TMB [66].
The incidence of patients with MSI-H profile CUPs is globally low,
with some variation depending on analysis technique: 1.6% with nextgeneration sequencing (NGS) analysis and immunohistochemistry [66]
and 2.4% via cfDNA analysis [61].
Table 3 illustrate data of potential predictive biomarkers of response
to immune checkpoint inhibitors in CUP.
How Effective Is The Current Standard Of Care?
One-size fits all approach
With the exception of the specific subsets of CUPs of favourable
prognosis (15%-20% of CUPs) that require specific treatments, doublet
combination chemotherapies, including platinum and taxanes, or other
6
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treatment, showing a median overall survival of 12.5 months, which
compares favourably with a historical control of 396 patients of CUPs
patients treated with empiric regimens in four other trials (9.1 months).
Methodological bias does not allow for highly reliable conclusions on
the basis of such an indirect comparison. Another non-randomised trial
assessing the combination of a platinum/taxane regimen with ever
olimus described a higher ORR (53% versus 26%, P = 0.0097) and a
better median overall survival (17.8 versus 8.3 months, P = 0.0052) in
the group of patients with a platinum/taxane-sensitive tissue of originpredicted tumours [93].
A randomised phase II trial, conducted by Hayashi and colleagues,
compared carboplatin/paclitaxel with site-specific treatment, resulting
in no benefit in the “empirical” arm [88], with definitive conclusions
difficult to draw because of limitations already described (out-of-date
standard arm for some primaries, low proportion of lung and breast
tissue of origin cancers due to environmental and ethnic differences).
The results of the prospective randomised phase III GEFCAPI 04 trial,
precisely addressing this question, were presented at the 2019 ESMO
Congress. The trial used a 92-gene real-time RT-PCR mRNA profiling
assay essentially providing a more sophisticated phenotype of the un
known primary tissue of origin based on a gene expression profile al
gorithm. Based on this profiling, annotated against a large reference
database, the study randomised between a control arm of empiric
chemotherapy (gemcitabine/cisplatin doublet) and a personalised
treatment arm (standard treatment of the suspected primary). The study
excluded specific subsets with favourable prognosis. It aimed to improve
median PFS by 3 months (from 5 to 8 months), and stratified for
geographic site, PS and LDH. With an accrual of 243 patients, this is the
largest CUP trial so far. GEFCAPI 04 failed to demonstrate an
improvement in either PFS (HR: 0.95 by central review) or OS (HR:
0.92). There was a trend for improved OS in patients with cancers whose
tissue of origin was unlikely to respond to gemcitabine/cisplatin (such as
melanoma, colorectal and kidney cancer), nevertheless non-significant
(HR: 0.74, p = 0.3347), owing to the small sub-cohort sizes. Overall,
outcomes of GEFCAPI 04 confirmed that the prognosis of CUPs
(excluding specific subsets) remains poor (median PFS of 5 months,
median OS of 10 months). A plausible explanation of this negative result
could be that a significant percentage of identified tissue of origin were
tumours for which a platinum-based regimen is standard-of-care treat
ment, such as pancreatico-biliary cancer and squamous cell carcinoma.
This could “annul” the effect of randomisation, as those patients
received a platinum-based doublet independently of the randomisation
arm. Moreover, a quarter of patients did not receive tailored treatment
for multiple reasons (urgent initiation of treatment, dramatic clinical
deterioration).

Targeted therapy based on molecular analysis
Targeting specific alteration
Case-reports describe successful treatment with targeted therapy in
CUP patients [98–106], yet the reporting bias does not allow for eval
uation of their real impact.
Targeted treatment used in an unselected fashion
The phase II single arm trial that assessed the triple combination of
everolimus and carboplatin/paclitaxel in untreated CUP patients
showed promising anti-tumoral activity (ORR: 36% in 45 assessable
patients); however, without a control arm, the benefit of the addition of
everolimus is unknown [93]. Furthermore, although the influence of
tissue of origin identification on outcome was assessed in this study, the
choice of everolimus was not based on molecular analysis.
A bevacizumab/erlotinib combination was tested in 51 poor prog
nosis patients, as first or second line, with only 10% of partial response
but an overall 71% disease control rate [107]. This led to test the
addition of bevacizumab/erlotinib to a carboplatin/paclitaxel regimen,
yielding interesting outcomes with a median overall survival of 12.6
months and an ORR of 53%, although a non-controlled study [108].
Another phase II randomised trial showed that the addition of belinostat
(a histone deacetylase inhibitor) to a carboplatin/paclitaxel combina
tion did not led to improved PFS as first line treatment [74]. Table 4 is
detailing data from phase II trials investigating targeted therapies in
CUP.
A paradigm shift recently occurred in oncology with the agnostichistology approval of biomarker-based tissue-agnostic treatments, such
as NTRK and RET inhibitors targeting the respective fusion-positive
cancers [109,110]. This could open a possible successful treatment op
tion for the subset of CUPs that features the above characteristics,
Table 4
Targeted therapies in CUP.
Author
(number of
patients)

Trial design
& Patients

Intervention

Ross et al.
(2021) 58
(n = 303)

Single arm
phase II
Newly
diagnosed
CUP

Ross et al.
(2021) 58
(n = 303)

Single arm
phase II
CUP
previously
treated or
untreated
with poorprognosis
clinical
features
Single arm
phase II
Newly
diagnosed
CUP

Everolimus 30
mg weekly
Carboplatine
AUC 6 and
paclitaxel 200
mg/m2
Bevacizumab
10 mg/kg
biweekly and
erlotinib 150
mg daily

Can Precision Medicine Change The Paradigm?
Despite celebrated examples of targeted therapy, the initial promise
of a complete transformation of oncology based on genomics has not
materialised [94]. Trials exploring the benefit of implementing molec
ular profiling in advanced cancers showed rather disappointing results,
leading authors to advocate for innovative approaches in precision
oncology [95,96]. In the ProfiLER trial, which included 2,579 adult and
paediatric patients with previously treated metastatic cancer,
molecular-based treatment has been recommended in 27% of patients,
with only 6% receiving it, leading to a response in 0.9% of the wholepopulation [97]. The deceiving results of molecular-based recom
mended therapy trials [96] are not weakening the principles of precision
oncology per se; they do, nevertheless, bring to light that beyond the thus
far approved targeted therapies, the magnitude of benefit stemming
from detailed molecular profiling remains, for now, small.

Hainsworth
et al. 108
(n = 60)

Hainsworth
et al. 74
(n = 89)

Randomized
phase II
Newly
diagnosed
CUP

Outcomes
Primary

Carboplatine
AUC 6 +
paclitaxel 175
mg/m2 +
bevacizumab
15 mg/kg on
day 1 every
21 days and
erlotinib 150
mg daily
Belinostat plus
paclitaxel/
carboplatine
versus
paclitaxel/
carboplatine

Response
rate: 36%

Median PFS: 4.1
monthsMedian
OS: 10.1 months

Response
rate: 10%

Median PFS: 3.9
monthsMedian
OS: 7.4 months

Response
rate: 53%

Median PFS: 8
monthsMedian
OS: 12.6 months

PFS ; 5.4
vs 5.3
months, p
= 0.85

Median OS: 12.4
vs 9.1 months, p
=
0.20Investigatorassessed response
rate: 45% vs 21%;
p = 0.02

PFS = progression free survival, OS = overall survival
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effectively bypassing tissue of origin. Nevertheless, these tumouragnostic biomarkers currently remain exceptions, and their real-life
impact is not yet clear [111,112]. The tissue of origin, even in the
emerging era of new tumour-agnostic biomarkers, remains of pivotal
importance in tumour response. The efficacy of biomarker-driven ther
apy varies greatly amongst tumour types. For instance, ORR to anti-PD1
pembrolizumab in MSI-H tumours varied from 57% in endometrial
cancers to 18% in pancreatic cancers and 0% in brain tumours [113].
BRAF inhibition is a striking illustration among others: the efficacy of
vemurafenib in targeting the BRAF V600E mutation observed in mela
noma patients [114] is not reproducible in colon cancers [115,116]. The
Cancer Genome Atlas analysis of 11,286 specimens confirmed that cellof-origin pattern is the dominating classification of cancers [117].
In known primary tumours, mechanisms for primary failure to tar
geted approaches, or secondary resistance, has been described: high
clonal variability and heterogeneity with clonal selection of resistant
clones [118], concomitant resistance mutations, redundancy of onco
genic pathways [119]. CIN is known to confer multidrug resistance
[120]. In which manner these known resistance mechanisms are
important specifically in CUPs is not perfectly understood.

What if we use precision medicine as a means to an end?
It is very likely that a subset of CUP patients in the unfavourable
subgroup would derive more benefit from molecular-driven treatment
than classical chemotherapy. Only a prospective study could identify the
real proportion of these patients. When such data are available, they
could bring an argument for incorporating molecular analyses, such as
NGS, into the initial diagnostic work-up of CUP; this was recently
advocated for patients for whom a dominant tissue of origin has not been
identified [133].
The reality is that guiding treatment based on optimisation of tissue
of origin identification has thus far failed to improve outcomes. As an
alternative approach, instead of aiming to identify tissue of origin
(phenotypic similarities), we could aim to identify the driver changes
behind these aggressive CUP lesions (genotypic driver changes) that can
be therapeutically targeted, eventually ignoring the tissue of origin. A
integrated approach could combine the two, generating both a detailed
tissue of origin -phenotypical analysis and a comprehensive genomic
profiling in the aim of identifying targetable alterations, which
approximately one-third of CUPs seem to harbour [58]. CUPISCO is an
ongoing phase II randomised trial that aims to explore molecularlyguided therapy for CUPs, using a platinum-based chemotherapy
comparator arm and a number of targeted therapies globally covering
for all targetable alterations with a proven benefit in oncology
(NCT03498521). CUPISCO is designed to show whether this approach
can improve outcomes. After 3 cycles of platinum-based chemotherapy,
non-progressing patients are randomised between the investigational
arm of maintenance therapy based on NGS analysis and a control arm
(further chemotherapy). This “switch maintenance” design selects for
patients responding to standard chemotherapy and positively primes the
study for better results, effectively excluding the poor responder patients
with very poor prognosis; per CUPISCO protocol, the latter patients will
receive second line molecularly guided therapy, and results will be
analysed on an exploratory basis. Results are highly anticipated. Should
CUPISCO attain its objective, coupled with the continuously enlarging
range of targeted therapies, it could bring about a meaningful change in
the outcomes of the disease, for which there has been little success so far.
Nonetheless, whether an achieved PFS benefit -the study primary
endpoint- would translate in either overall survival benefit or better
quality of life in this lethal disease remains the main clinically mean
ingful questions.
However, the CUPISCO investigators have already reported on bar
riers in enrolling patients. Reporting on the first 157 patients, 58% failed
the screening process for several reasons such as issues in identifying this
subset of CUP patients, insufficient quality or quantity of tissue available
for screening molecular analysis and the declining performance status of
prospective candidates [134].
There is a clear need to identify driver genomic abnormalities out of
the potential list of pathogenic aberrations identified through molecular
profiling. It might actually be more pertinent to spot the differences
instead of the similarities with the presumed tissue of origin. In this
process, the critical assessment of profiling-identified changes, the
interpretation of variants of uncertain significance and the identification
of potential germline variants are challenges that require multidisci
plinary review and the linking to clinical trials networks [135]. This
should be made within molecular tumour boards.
Accrual is a major issue in running specific CUPs trials, explaining
why only four of them are actually recruiting (Table 5).

Role of immune checkpoint inhibitors (CPI)
A greater number of patients presenting with CUPs are treated with
immune checkpoint inhibitors (CPI): either inside clinical trials, through
the FDA approval in case of for microsatellite instability-high (MSI-H) or
mismatch repair deficient tumours (MMRd)[121], or off-label. Efficacy
biomarkers are needed across cancer types for CPI, and the same applies
for CUP. Overall, PD-L1 expression alone is not a sufficient biomarker to
predict response to CPI across cancer types [122–124]. Tumour muta
tional burden (TMB) as a predictive biomarker to CPI treatment has
shown clinical impact in some studies [125–128]. However, the real
predictive value of TMB remains unclear and needs further investigation
[129].
Anecdotal cases showed clinical activity of CPI in CUPs irrespective
of the presumed tissue of origin [130,131]. NivoCUP, an open-label
phase II trial, is the first trial in this setting to be reported. The effi
cacy of nivolumab in the unfavourable subset of CUP patients was
assessed, with ORR as the primary endpoint [132]. Most of patients
(80.3%) were previously treated. In this population (n = 45), the ORR
was 22%, with two complete response (4.4%), a disease-control rate of
53.3% and a median duration of response of 12.4 months. Median PFS
and OS in this group were 4.0 months and 15.9 months respectively. The
reported median PFS was rather short without a plateau that would
indicate long term responders. Of note, among the 45 patients previ
ously treated, 20% had 2 prior lines of therapy and 22% has 3 prior lines,
which obviously represents a very highly selected population, thus
making cross-trial comparison meaningless. In the same work, a very
low number of patients were treated upfront with nivolumab with
18.2% ORR. There is indeed signal of efficacy, with the caveat of highly
selected patients. The need for predictive biomarkers in order to identify
the 20% of CUP patients that will indeed respond to CPI treatment is
crucial.
Other trials addressing the role of CPI in CUPs are ongoing. Selection
of patients for treatment, based on clinical features and biomarkers, are
critical. The ongoing CUPISCO trial includes an atezolizumab mono
therapy arm for the TMB-high patients, and a combination chemo
therapy/atezolizumab arm for patients with TMB-low or unknown
tumours.
While awaiting these results, we must be aware of the specific
phenotypic and biologic pattern of the unfavourable prognostic CUPs
tumour: how chromosomal instability, a hallmark of unfavourable
CUPs, could impact response to CPI remains an open question [43,44].

Conclusion
CUPs could be viewed as the quintessence of oncology, with many
transversal biological issues, challenges that are found across oncology
in general, but crucially with urgently needed answers to improve pa
tient’s clinical outcomes. Although a highly heterogeneous group of
cancers, CUPs can be categorised in two very distinct groups, at levels of
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Table 5
Ongoing recruiting trials specifically designed for CUP patients.
Trial
name

NTC

Title

Phase

Arms

Setting

CUPSICO

NCT03498521

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted
Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in
Patients With Cancer of Unknown Primary Site

II

First line poor
prognosis CUP

CheCUP

NCT04131621

Nivolumab/Ipilimumab in Second Line CUP-syndrome

II

Mutliples arms :
- Platinum-basedmolecularly guided
therapy
Single arm

CUPem

NCT03752333

Trial of Pembrolizumab in Cancer of Unknown Prima

II

Single arm

CUP

NCT03391973

Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary
Site

II

Single arm

biology, clinical presentation, treatment strategies and prognosis. The
first group of specific subset CUPs behave closely like their counterpart
known primaries, and benefit from same treatment strategies leading to
same outcomes. Whether molecular profiling can enlarge this group of
good-prognosis, specific-subset CUPs is an interesting point that remains
to be seen.
The vast majority of CUP patients belongs to the unfavourable, nonspecific subset CUP group. They present with very poorly differentiated
tumours, high chromosomal instability, aggressive and unpredictable
metastatic pattern, and poor prognosis. A true “molecular signature” has
not yet been identified, yet chromosomal instability seems to be a
hallmark of unfavourable CUPs. The main issue pertains to this unfav
ourable subgroup of CUP patients, where almost no improvement has
been achieved for decades. Recent randomised trials have shown that
tissue of origin classifiers used to guide treatment do not modify out
comes. Molecular analysis in order to find matched targeted therapies
could probably select a proportion of patients that could benefit from
these treatments, but prospective evidence is awaited. Within this
context, whether immune checkpoint inhibitors could be beneficial re
mains an ongoing question.
A promising area of research focus could be the possibility of iden
tifying a “feature signature” within the unfavourable group of CUPs that
could be found in an “-omics” levels and could transcend the tissue of
origin pattern (metabolism, microenvironment, non-coding DNA region,
epigenetics). How to target chromosomal instability is also of major
interest, as well as how to combine treatment to prevent acquired
resistance.

Second line poor
prognosis CUP
2 cohorts: first line and
second line settings
First line poor
prognosis CUP
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